Last reviewed · How we verify
Enteric coated sevelamer — Competitive Intelligence Brief
phase 2
Phosphate-binding agent
Nephrology
Small molecule
Live · refreshed every 30 min
Target snapshot
Enteric coated sevelamer (Enteric coated sevelamer) — Genzyme, a Sanofi Company. Sevelamer binds to phosphate ions in the gastrointestinal tract, reducing phosphate absorption.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Enteric coated sevelamer TARGET | Enteric coated sevelamer | Genzyme, a Sanofi Company | phase 2 | Phosphate-binding agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Phosphate-binding agent class)
- Genzyme, a Sanofi Company · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Enteric coated sevelamer CI watch — RSS
- Enteric coated sevelamer CI watch — Atom
- Enteric coated sevelamer CI watch — JSON
- Enteric coated sevelamer alone — RSS
- Whole Phosphate-binding agent class — RSS
Cite this brief
Drug Landscape (2026). Enteric coated sevelamer — Competitive Intelligence Brief. https://druglandscape.com/ci/enteric-coated-sevelamer. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing